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THE aim  of  this  study  was  to  assess  whether  inter-
leukin-10 (IL-10) and/or transforming growth factor
b -1 (TGFb 1) downregulate HLA-DR expression using
the  HT29  cell  line  as  a  model  of  colonic  epithelial
cells. HLA-DR expression was induced in HT29 cells
with g -interferon. The effects of IL-10 alone, TGFb 1
alone,  and  IL-10  and  TGFb 1 in  combination  were
studied. HLA-DR expression was assessed using flow
cytometric  analysis.  g -Interferon  induced  HLA-DR
expression  in  a  dose-dependent  fashion.  In  the
absence  of  g -interferon,  neither  IL-10  nor  TGFb 1
induced HLA-DR expression. In isolation, neither IL-
10  nor  TGFb 1 downregulated  HLA-DR  expression.
When IL-10 and TGFb 1 were added in combination,
small  (6–30%)  statistically  significant  reductions  in
HLA-DR  expression  were  seen.  The  biological  sig-
nificance is unclear.
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Introduction
HLA-DR molecules are cell surface heterodimers that
act  as  immune  recognition molecules. A  variety  of
antigen-presenting-cells present antigen in association
with HLA-DR to lymphocytes. This interaction leads to
lymphocyte  activation  and  proliferation,  and  thus
promotes  inflammatory  responses.1 In  addition  to
constitutive  expression  on  a  variety  of  cell  types
including lymphocytes, macrophages, vascular endo-
thelium and some epithelial cells,2 expression of HLA-
DR molecules is induced in a much wider range of cell
types in the presence of inflammation.3
Under  normal  conditions,  HLA-DR  molecules  are
not  expressed  by  colonic  epithelium,4 however,
colonic epithelial cell expression of HLA-DR is seen in
a variety of inflammatory bowel diseases.5,6 In vitro
studies  have  shown  that  HLA-DR-bearing  colonic
epithelial cells can present antigen to mucosal lym-
phocytes.7,8 It is thus likely that HLA-DR expression
by colonic epithelial cells is an important step in the
generation of mucosal immune responses.
The  mechanisms  that  regulate  colonic  epithelial
cell expression of HLA-DR are being defined. Induc-
tion  of  HLA-DR  is  mediated  by  pro-inflammatory
cytokines  such  as  g -interferon.3,9 g -Interferon  has
been  widely  used to  induce  HLA-DR expression in
human gastrointestinal carcinoma cell lines.10–12 The
mechanisms by which colonic epithelial cell HLA-DR
expression is downregulated when mucosal inflam-
mation resolves have not been identified.
Some cytokines have immunosuppressive proper-
ties, some of which may be due to downregulation of
HLA-DR expression in antigen presenting cells. Inter-
leukin-10  (IL-10)  and  transforming  growth  factor  b
(TGFb ) are of particular interest. IL-10 has a variety
of  inhibitory  actions  including  inhibition  of
T -lymphocyte activation/function as well as inhibition
of the production of chemokines and cytokines.13–15
IL-10 inhibits g -interferon-induced expression of MHC
Class II antigens in a variety of cell types.16–19 Mice
that are deficient in the IL-10 gene develop chronic
enterocolitis.20 TGFb is present throughout  the gas-
trointestinal mucosa21 and has a variety of inhibitory
functions such as inhibition of epithelial cell prolifera-
tion.22 TGFb also down regulates HLA-DR expression
in  a  variety  of  cell  types,  including  a  colonic
carcinoma  cell  line.23 As  with  the  IL-10 ‘knockout’
mouse,  mice  with  disrupted TGFb genes  develop
multifocal  chronic  inflammation  which  includes
involvement of the gastrointestinal tract.24 With these
observations  in  mind,  we  hypothesized  that  IL-10
and/or TGFb downregulate colonic epithelial HLA-DR
expression.
The  aim  of  this  series  of  experiments  is  to  test
whether IL-10 and TGFb down-regulate g -interferon-
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model of colonic epithelium. The cell line selected for
use in this study (HT29/19a clone) is a well differ-
entiated human colonic carcinoma cell line that forms
monolayers  with  ultrastructural  and functional  sim-
ilarities to normal colonic epithelium.25–28 The HT29
cell line has been used in previous studies examining
the effects of different  agents on colonic epithelial
cell expression of HLA-DR.9,10,12
Methods
Cell line
The HT29/19a colonic carcinoma cell line was a gift
of  Professor  Laboisse.26 The  stock  cultures  were
maintained at 37°C in an atmosphere of 5% CO2 in
Dulbecco’s modified Eagle medium (DMEM) supple-
mented with glucose 4500mg/l, 10% heat inactivated
fetal calf serum and 1% antibiotic solution (penicillin
10000IU/ml and streptomycin 10000U/ml).
Cytokines
Human g -interferon, IL-10 and TGFb 1 were purchased
from  Genzyme  (Kent, UK). All cytokines were pre-
pared as sterile, filtered solutions in culture media,
and then stored frozen. Although specific bio-assays of
these preparations were not performed for this series
of  experiments,  all  of  these  cytokine  preparations
demonstrated biological  activity  in cell  culture  sys-
tems used by other workers in our group.
Experimental incubations
For each experiment, HT29/19a cells were harvested
from the stock cultures and added to separate 4.5cm2
wells in a 12-well culture plate. The cells were then
incubated  for  72h.  Each  experiment  was  done  in
quadruplicate.
Experimental protocols
HLA-DR  expression  was  induced  by  g -interferon.
Experiments were performed using concentrations of
g -interferon of 10U/ml and 100U/ml. The effects of IL-
10 and TGFb 1 were assessed over cytokine concentra-
tions  of  0,  1,  10  and  100U/ml.  Three  series  of
experiment were performed. Firstly, the effect of IL-10
was  examined.  Secondly,  the  effect  of TGFb 1 was
examined, and thirdly, the effect of IL-10 and TGFb 1 in
combination was examined. Within each experimental
series, two further experiments were set up. In one set
of cultures, cytokine was added at the same time as
g -interferon was added (co-incubation). In a separate
set of cultures, cytokine was added 24h prior to the
addition of g -interferon (pre-incubation).
A further series of experiments were performed to
examine the hypothesis that mucosal lamina propria
lymphocytes from  uninflamed colonic mucosa  may
inhibit colonic epithelial cell expression of HLA-DR.
Colonic mucosal  lamina propria lymphocytes  (LPL)
were  isolated  from  uninflamed  colonic  mucosa
obtained from surgical resection specimens using a
previously  described  protocol.29 All  tissue  was
obtained from normal appearing mucosa at least 5cm
from any macroscopic disease. The diagnoses of the
patients included carcinoma (six patients) and ischae-
mic  colitis  (one  patient).  The  isolated  LPL  were
maintained at a concentration of 106 cells per ml in
RPMI  culture  media  supplemented  with  10%  heat
inactivated  fetal  calf  serum  and  1%  antibiotic
solution   (penicillin 10000IU/ml  and streptomycin
10000U/ml). Following isolation, the LPL were main-
tained in culture at 37°C in an atmosphere of 5%  CO2
for 24h. The cultures were then spun down at 750 3
g, and the supernatants collected and frozen at –70°C.
The  LPL  supernatants  were  thawed  at  37°C  and
diluted with supplemented DMEM at a ratio of 1:2
(supernatant:DMEM). This mixture was then used to
culture  HT29/19a  cells  in  a  similar  fashion  to  the
cytokine  experiments.  The  control  cultures  were
maintained in a 1:2 mixture of supplemented RPMI
and DMEM. Due to limited volumes of supernatant,
this experiment was only done using g -interferon of
100U/ml. The composition of the supernatants was
not evaluated.
Flow cytometry
At the end of the incubation period, the monolayers
were  disrupted and single cell suspensions created
using EDTA. Cell viability was assessed by Trypan Blue
staining, and any samples with viability was less than
90% were discarded. The cells were then stained with
fluoroscein  isothiocyanate  (FITC)-conjugated  anti-
HLA-DR  (Dako),  a  mouse  anti-human  monoclonal
antibody to the b chain of HLA-DR. FITC-conjugated
anti-IgG1  (Becton Dickinson) was  used as  the  neg-
ative isotype control. The cells were fixed with 1%
paraformaldehyde  in  PBS/0.1%   sodium  azide,  and
analysed within 2–4 days.
The samples were analysed using a Becton Dick-
inson flow cytometer using LYSIS II software. Fluores-
cence  histograms  for  the  anti-HLA-DR  cells  were
generated for each  sample. Five thousand cells per
gate were counted. The data recorded included (a) the
percentage  of  cells  of  each  sample  that  showed
fluorescence with the FITC-labelled anti-HLA-DR, and
(b)  the  mean/median  fluorescence  intensity of  the
stained cells.
Statistical analysis
The data from each experimental series was analysed
using  a  one-way  analysis  of  variance  using  Excel®
(Microsoft) software.
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Effect of g -interferon
Cells were 70–80% confluent at the time of harvest.
The percentage of cells staining positive for HLA-DR
increased  with  increasing  dose  of  g -interferon,
although no further increases were noted at concen-
trations of g -interferon in excess of 50U/ml. Within
the population of cells staining positive for HLA-DR,
there were no significant differences between median
or mean fluorescence intensity with cells exposed to
different doses of g -interferon. The viability of cells in
all  experiments  ranged from  92%   to  95% ,  with  no
significant  differences  observed  across  any  of  the
different interventions.
Some  variation  in  the  sensitivity  of  the  cells  to
g -interferon was noted from passage-to-passage. This
occurred despite  the  use  of  identical  reagents  and
culture  protocols,  and in the  absence  of  infection.
Similar  variation  has  been  seen  by  other  workers
using HT29 cell line.12 In view of this observation, the
direct comparison of results obtained from different
passage generations is invalid. The cellular basis of this
variability is unclear.
Effects of isolated IL-10 and TGFb -1
Neither IL-10 nor TGFb 1 in isolation, in the absence
of  g -interferon,  induced  expression  of  HLA-DR  in
HT29/19a cells. Neither co-incubation nor pre-incu-
bation  with  IL-10  resulted in any  significant  differ-
ences in the percentage of cells staining positive for
HLA-DR at either concentration of g -interferon (Fig.
1). Within  the  population  of  cells  staining  positive
for  HLA-DR,  there  were  no  significant  differences
between  median  or  mean  fluorescence  intensity
with  cells  exposed  to  different  doses  of  IL-10  at
either  concentration  of  g -interferon.  In  identical
experiments,  isolated TGFb 1 had  no effect  on HLA-
DR expression (Fig. 2).
Effects of combination IL-10 and TGFb -1
When IL-10 and TGFb 1 were added in combination in
the absence of g -interferon, no expression of HLA-DR
was  observed. In  the  presence  of  g -interferon,  the
combination of IL-10 and TGFb 1 significantly reduced
the percentage of cells expressing HLA-DR in a dose
dependent  fashion  (Fig.  3). The  magnitude  of  the
maximum reduction in percentage of cells expressing
HLA-DR was greater in the groups incubated with the
lower concentration of g -interferon. Despite achiev-
ing statistical significance, the absolute reductions in
expression  of  HLA-DR  were  small  in  each  group
(6–30%). The  magnitude  of  the  reductions  in  per-
centage of cells expressing HLA-DR was greater in the
pre-incubation  groups  than  in  the  co-incubation
groups (for g -interferon = 10U/ml, 30% vs. 6% ; for
g -interferon = 100U/ml, 12.1% vs. 8.3%). Within the
population of cells staining positive for HLA-DR, there
were no significant differences between  median or
mean  fluorescence  intensity  with  cells  exposed  to
different doses of IL-10 and TGFb 1 at either concentra-
tion of g -interferon.
Interleukin-10, TGFb -1 and HLA-DR expression
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FIG. 1. The effect of interleukin-10 on g -interferon induced
HLA-DR expression. (The error bars represent ±1 standard
deviation.) For all ANOVA, P-value >0.05.
FIG.  2.  The  effect  of  transforming  growth  factor  g -1  on
g -interferon  induced  HLA-DR  expression.  (The  error  bars
represent ±1 standard  deviation.) For all ANOVA, P-value
>0.05.
FIG. 3. The effect of combination interleukin-10 and trans-
forming growth factor g -1 on g -interferon induced HLA-DR
expression. (The error bars represent ±1 standard deviation.)
*P-value for ANOVA <0.05.Effect of LPL supernatants on HT29/19A
HLA-DR expression
No significant differences in HLA-DR expression were
observed  between  cells  cultured  with  LPL  super-
natant/DMEM culture medium and cells cultured with
DMEM culture medium alone.
Discussion
On the basis of these results, neither TGFb 1 nor IL-10
acting in isolation downregulate g -interferon-induced
expression of HLA-DR within this experimental sys-
tem. There are no other published data examining the
effect of IL-10 on expression of HLA-DR in a colonic
epithelial cell line. Previous studies using TGFb 1 have
shown  conflicting  results.  Darley  et  al.11 demon-
strated that TGFb 1 inhibited induced expression of
HLA-DR in a variety of cell lines. However, they found
that  nine  different  colorectal  cell  lines  (including
HT29)  were  resistant  to  the  inhibitory  effects  of
TGFb 1 on both epithelial proliferation and epithelial
expression of MHC molecules including HLA-DR. In
contrast,  Donnet-Hughes  et  al.12 found  that TGFb 2
downregulated g -interferon-induced HLA-DR expres-
sion by up to 75%. Several factors may explain the
discrepancies between these different studies.
Firstly, the absence of inhibitory effects seen in the
current study may reflect limitations of the experi-
mental model. As Darley et al.11 demonstrated, there is
wide variation in the sensitivity of different cell lines to
the effects of specific cytokines. It is interesting to note
that even using the same cell line (HT29), different
groups have generated diverse results. For example,
our group has previously found that HT29 cells grown
in glucose containing media do not show induction of
HLA-DR on exposure to g -interferon,30 but this lack of
responsiveness has  not been found by other  work-
ers,12 or in our experience with the current clone of
HT29. These discrepancies may reflect differences in
the degree of differentiation of the HT29 clones, as
glucose influences the differentiation of these cells in
culture.25,27,30 Discrepancies between the results of
different groups may represent subtle differences in
the functional  characteristics between the different
clones of HT29 cells used.
A further confounding factor is that use of color-
ectal carcinoma cell lines is only an approximation of
the  functional  behaviour  of  non-malignant  cells.
Recent work has shown some colorectal carcinoma
cell  lines,  including  HT29,  have  a  mutation  in  the
TGFb receptor that renders them insensitive to the
effects  of  TGFb .31  The  ideal  experimental  model
would be to use non-malignant epithelial cells. Whilst
isolation protocols for human colonic epithelial cells
are described,7,32,33 it has been difficult to maintain
non-malignant  colonic  epithelial  cells  in  long-term
cell culture.34
Methodological aspects of the experimental model
may also have contributed to the failure to observe
any  inhibitory  effects  of  isolated  cytokines  in  the
current work. One factor worth consideration is the
incubation time used. Donnet-Hughes et al.13 incu-
bated cultures for 24–48h and changed the cytokine
containing media daily. In contrast, the cell cultures in
our  series  were  maintained  for  72h  without  any
replenishment of the media. As cytokines are labile
and have very short half lives in vivo, it is conceivable
that the relatively long incubation time and the lack of
replenishment of the cytokines may have reduced the
sensitivity of the experimental system for detection of
cytokine-mediated changes in HLA-DR expression.
In contrast to the effects of TGFb 1 and IL-10 alone,
small reductions in induced HLA-DR expression were
observed when both cytokines were added in combi-
nation. The magnitude of the reductions in HLA-DR
expression are relatively small compared with those
observed by other workers.13As has been observed in a
previous study,12 the magnitude of the reduction in
HLA-DR  expression  is  greater  when  the  induction
signal is smaller (i.e. at lower doses of g -interferon that
are not within the saturated portion of the g -interferon/
HLA-DR expression dose response curve). Although
the observed reductions in HLA-DR expression may
represent  a  genuine  biological  effect,  the  absolute
magnitude of the reduction in HLA-DR expression is
small and may simply represent non-specific effects of
having extra peptide in the culture media.
It  is  biologically  plausible  that TGFb 1 and  IL-10
acting in combination have much greater inhibitory
effects  on HLA-DR  expression than  either  cytokine
acting alone. It has been shown that TGFb 1 and IL-10
act at different levels of cellular function. For exam-
ple, IL-10 has been shown to downregulate macro-
phage TNF-a production by inhibiting production of
TNF-a mRNA  whereas TGFb 1 inhibits  macrophage
TNF-a production by inhibiting TNF-a release.35
It is also possible that the small reductions in HLA-
DR expression demonstrated in the current study have
no relevance in vivo. Other workers have shown that
the inhibitory effects of cytokines such as IL-10 are cell-
type specific and also depend on the type of inducing
signals  used.17 A  major  limitation  of  the  current
experimental model is that it ignores the interactions
of  other  cell  types  found  within  in  the  mucosal
microenvironment in vivo. It is possible that the anti-
inflammatory properties of IL-10 and TGFb 1 in vivo
are  mediated  through  other  cell  types  such  as
macrophages and neutrophils,14 and that epithelial cell
HLA-DR expression is not the direct target of these
cytokines in vivo. Even if the epithelial cells are not the
direct targets of IL-10 and TGFb 1, these cytokines may
inhibit epithelial cell HLA-DR expression indirectly. For
example,  IL-10  is  a  potent  inhibitor  of  monocyte
production of g -interferon,36 which will in turn inhibit
the HLA-DR expression by epithelial cells.
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colonic epithelial HLA-DR expression is not necessary
in  vivo because  of  the  kinetics  of  the  colonic
epithelial  turnover. The  colonic  epithelium  is  con-
stantly turning over with continuous loss of epithelial
cells and replacement of these cells from proliferation
in  the  colonic  crypts.  In  this  system,  the  loss  of
inflammatory signals such as g -interferon maybe all
that is necessary to result in the re-appearance of HLA-
DR-negative  epithelial  cells.  Our  observation  that
lamina propria lymphocyte supernatants from unin-
flamed  mucosa  do  not  downregulate  g -interferon-
induced HLA-DR  expression is consistent  with  this
hypothesis.
In summary, IL-10 and TGFb 1 in combination, but
not acting alone, directly downregulate g -interferon-
induced  HLA-DR  expression  in  colonic  epithelial
cells. The magnitude of these effects are small, and
may reflect limitations of the specific experimental
model. The biological relevance of these findings is
unclear. Given the potential therapeutic significance
of IL-10 and TGFb 1 in controlling mucosal inflamma-
tion, further investigation is warranted.
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